Background: Alzheimer’s disease (AD) is the most common neurodegenerative disorder, the NLRP3 inflammasome has been shown to play a pivotal role in the pathogenesis of AD, and with increasing attention to its involvement in AD. Therefore, we applied bibliometric methods to describe the current research status of the NLRP3 inflammasome in AD. This study aims to analyze the research trends and hotspots in this field from 2013 to 2024, providing valuable insights for AD research. Methods:We have selected research on the NLRP3 inflammasome in Alzheimer's disease from the Web of Science Core Collection, with the time range from January 1, 2013, to November 30, 2024, and exported all publications in plain text format. Visualization analysis was performed using CiteSpace 6.4.R1, VOSviewer 1.6.20, and Scimago Graphica 1.0.46. Results: A total of 759 publications related to the NLRP3 inflammasome in Alzheimer's disease were included in this study. The number of annual publications showed a general upward trend. The top three countries in terms of publication volume were China, the United States, and Italy. The University of Manchester was the institution with the highest number of publications. The author with the most publications was Michael Heneka, while the most cited author was Eicke Latz. The International Journal of Molecular Sciences published the highest number of articles and was also the most frequently cited journal. The most common keywords included Alzheimer’s disease, NLRP3 inflammasome, neuroinflammation, Aβ, and microglia. Conclusion: The primary research hotspots in this field focus on the role of NLRP3 in AD pathology, its potential as a therapeutic target, and strategies to modulate neuroinflammation through targeting the NLRP3 inflammasome. Future research should further investigate the interactions between NLRP3 and other molecular pathways, assess its clinical therapeutic potential, and provide new insights and strategies for the early diagnosis and treatment of AD.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its Supporting Information files.